Janux Therapeutics, Inc. (JANX)
| Market Cap | 882.06M |
| Revenue (ttm) | 10.00M |
| Net Income (ttm) | -113.63M |
| Shares Out | 60.83M |
| EPS (ttm) | -1.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,087,173 |
| Open | 15.12 |
| Previous Close | 15.23 |
| Day's Range | 14.33 - 15.39 |
| 52-Week Range | 12.12 - 35.34 |
| Beta | 2.81 |
| Analysts | Buy |
| Price Target | 47.00 (+224.14%) |
| Earnings Date | May 8, 2026 |
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008... [Read more]
Financial Performance
In 2025, Janux Therapeutics's revenue was $10.00 million, a decrease of -5.55% compared to the previous year's $10.59 million. Losses were -$113.63 million, 64.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for JANX stock is "Buy." The 12-month stock price target is $47.0, which is an increase of 224.14% from the latest price.
News
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it ...
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the f...
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomina...
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial r...
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell En...
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading.
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate c...
Janux dives as gaps in prostate cancer study data worry investors
Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.
Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.
Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer.
Janux Therapeutics Transcript: Investor Update
JANX007 demonstrates durable responses and manageable safety in MCRPC, with strong PSA reductions and favorable RPFS, especially in taxane-naive and low tumor burden patients. Q2W dosing is preferred, and the program is advancing in both monotherapy and combination settings, targeting earlier lines and PARP inhibitor-refractory populations.
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC.
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Transcript: R&D Day 2025
Three new programs—PSMA CD28 TRACIr, TROP2 TRACTr, and CD19 ARM—expand a robust pipeline targeting oncology and autoimmune diseases. Strong preclinical and early clinical data support best-in-class potential, with significant market opportunities and a solid financial position to reach key milestones.
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual R&D Day on July 24, 2025.
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...